SCHEMBL6340616

SCHEMBL6340616

O=C(Cc1ccc(Oc2ccc3cc(OCc4ccccc4)ccc3c2)nc1)Nc1ccccc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
HCAR2 Q8TDS4 6/20 0.53
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 2/20 0.45
PKM P14618 1/20 0.45
KDM6B O15054 1/20 0.44
KDM4D Q6B0I6 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
POLB P06746 1/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOA1 Q15788 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6338905 0.92 KDM4E (0.47) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL6582641 0.91 HCAR2 (0.62) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL14513318 0.88 MEN1 (0.61) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL6348822 0.87 CTSV (0.48) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL6346488 0.87 CTSV (0.46) MEN1KMT2ACASP3SENP8SENP7
SCHEMBL6339661 0.83 ALDH1A1 (0.53) MEN1KMT2AALDH1A1KDM4EPOLB
SCHEMBL6341556 0.83 ALOX5 (0.51) MEN1KMT2AALDH1A1KDM4EPOLB
SCHEMBL6339149 0.83 SERPINE1 (0.49) MEN1KMT2AALDH1A1KDM4EPKM
SCHEMBL6349056 0.82 HCAR2 (0.49) KMT2AHCAR2ALDH1A1KDM4EPOLB
SCHEMBL6339038 0.81 CTSV (0.48) MEN1KMT2ACTSVCTSLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1245380-C Anthranilic acid derivatives TEIJIN LTD (JP) 2006-03-15 CN disclosed
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
CN-1319086-A Anthranilic acid derivatives TEIJIN LTD (JP) 2001-10-24 CN disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 MEN1 2656/4885KMT2A 1762/4885CASP3 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.